Alvarez Ralph 4
4 · ELI LILLY & Co · Filed Apr 21, 2026
Research Summary
AI-generated summary of this filing
Eli Lilly (LLY) Director Ralph Alvarez Receives 13.498-Share Award
What Happened
Ralph Alvarez, a member of Eli Lilly & Co.'s board of directors, was granted 13.498 shares (transaction code A) on 2026-04-20 at an effective price of $919.90 per share, a total value of approximately $12,417. This was an award of company stock units as director compensation, not an open-market purchase or sale.
Key Details
- Transaction date and terms: 2026-04-20; 13.498 shares at $919.90 per share (total ≈ $12,417).
- Filing date: Form 4 filed 2026-04-21 (reported one day after the transaction — timely).
- Shares owned after transaction: Not specified in the provided filing excerpt.
- Footnote F1: Alvarez elected to defer the shares in lieu of cash under the Lilly Directors' Deferral Plan; units will be settled in common stock upon his separation from service.
- Footnote F2: Alvarez disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest.
Context
This was a routine director compensation award (deferred stock units), which differs from a purchase or sale and should be interpreted as compensation, not a direct trading signal. The deferral means Alvarez will receive actual shares later (upon separation), and the filing includes the standard disclaimer about beneficial ownership.
Insider Transaction Report
- Award
Common Stock
[F1]2026-04-20$919.90/sh+13.498$12,417→ 55,614.713 total
- 758(indirect: By Trust)
Common Stock
[F2]
Footnotes (2)
- [F1]At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service.
- [F2]The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.